p38 MAPK might be at play as a pivotal intracellular signal transducer in endometriosis

In: Ensho Saisei · 2004 · vol. 24(6) , pp. 629–633 · doi:10.2492/jsir.24.629 · W2035973029
article OA: diamond CC0
AI-generated summary by claude@2026-06, 2026-06-09

Inhibition of p38 MAPK with FR 167653 reduced endometriotic lesion growth and intraperitoneal inflammation in a mouse model.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Given the current theory of inflammatory changes being involved in the progression of endometriosis, MAPKs might be at play as pivotal intracellular signal transducers in endometriotic cells and thus have a pathophysiological role in the disease. In vitro study using endometriotic cell, all the MAPK inhibitors examined suppressed IL-1β-induced secretion of IL-6 and IL-8, and IL-1β-induced expression of COX-2 in endometriotic cells. Among MAPK inhibitors, p38MAPK inhibitor seemed to have the best potential to block inflammation. Then, the authors evaluated the effect of FR 167653, a p38MAPK inhibitor, on the development of endometriotic lesions and on the intraperitoneal inflammatory status using experimental model mice for endometriosis. FR 167653, a p38 MAPK inhibitor, caused a reduction in the growth of endometriotic lesions, coupled with the suppression of intraperitoneal inflammation. Thus, p38 MAPK inhibitors could have the therapeutic potential for endometriosis.

My notes (saved in your browser only)

Condition tags

endometriosis

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (13)

Source provenance

openalex
last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0 · commercial use OK